Literature DB >> 6787722

Gold therapy in rheumatoid arthritis.

F L Majoos, P Klemp, O L Meyers, B Briggs.   

Abstract

During the period 1971-1979, 114 patients with rheumatoid arthritis attending the arthritis clinics at Groote Schuur Hospital and Princess Alice Orthopaedic Hospital were treated with gold sodium aurothiomalate (Myocrisin). Data obtained from 104 completed protocols showed that 70 patients (67,3%) benefited from chrysotherapy. Forty of these patients went into complete remission. Therapy was discontinued in 58 patients, side-effects accounting for this in 33 cases (31,8%). Adverse reactions included skin rashes in 41 (39%) and renal complications in 16 (14%); 7 (6%) developed haematological complications, which resulted in death in 2 cases. HLA tissue typing in 37 patients with side-effects showed no increase in the HLA Dw2 or HLA Dw3 antigen. There was, however, a significant increase in the HLA DRw4 antigen in both Whites and Coloureds (P less than or equal to 0,008 and P less than or equal to 0,001 respectively).

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 6787722

Source DB:  PubMed          Journal:  S Afr Med J


  3 in total

1.  Polymorphism of major histocompatibility complex extended haplotypes bearing HLA-DR3 in patients with rheumatoid arthritis with gold induced thrombocytopenia or proteinuria.

Authors:  D P Singal; B Reid; D Green; M D'Souza; W G Bensen; W W Buchanan
Journal:  Ann Rheum Dis       Date:  1990-08       Impact factor: 19.103

2.  HLA-D region genes and rheumatoid arthritis (RA): importance of DR and DQ genes in conferring susceptibility to RA.

Authors:  D P Singal; D Green; B Reid; D D Gladman; W W Buchanan
Journal:  Ann Rheum Dis       Date:  1992-01       Impact factor: 19.103

3.  HLA antigens and toxic reactions to sodium aurothiopropanol sulphonate and D-penicillamine in patients with rheumatoid arthritis.

Authors:  P Perrier; C Raffoux; P Thomas; J N Tamisier; M Busson; A Gaucher; F Streiff
Journal:  Ann Rheum Dis       Date:  1985-09       Impact factor: 19.103

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.